Jeff Johnson
Stock Analyst at Baird
(4.63)
# 229
Out of 4,996 analysts
148
Total ratings
57.43%
Success rate
28.56%
Average return
Main Sectors:
Stocks Rated by Jeff Johnson
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| DXCM DexCom | Maintains: Outperform | $112 → $90 | $67.10 | +34.13% | 15 | Sep 26, 2025 | |
| COO The Cooper Companies | Maintains: Outperform | $97 → $85 | $67.55 | +25.83% | 18 | Aug 28, 2025 | |
| ALC Alcon | Maintains: Outperform | $108 → $95 | $73.92 | +28.52% | 10 | Aug 21, 2025 | |
| BBNX Beta Bionics | Maintains: Neutral | $15 → $17 | $19.53 | -12.95% | 2 | Jul 30, 2025 | |
| HSIC Henry Schein | Downgrades: Neutral | $82 → $72 | $66.04 | +9.02% | 10 | Jul 14, 2025 | |
| NVST Envista Holdings | Upgrades: Outperform | $21 → $23 | $20.35 | +13.02% | 10 | May 27, 2025 | |
| ZBH Zimmer Biomet Holdings | Maintains: Outperform | $130 → $115 | $98.24 | +17.06% | 14 | May 6, 2025 | |
| TNDM Tandem Diabetes Care | Maintains: Neutral | $33 → $24 | $12.00 | +100.00% | 16 | May 1, 2025 | |
| SYK Stryker | Maintains: Outperform | $378 → $405 | $369.02 | +9.75% | 11 | Oct 30, 2024 | |
| ALGN Align Technology | Maintains: Outperform | $325 → $276 | $126.19 | +118.72% | 18 | Oct 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $180 → $238 | $318.00 | -25.16% | 12 | Dec 21, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $67 → $70 | $29.99 | +133.41% | 2 | Aug 4, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $53 → $61 | $14.90 | +309.40% | 4 | Jul 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $78 → $67 | $12.50 | +436.00% | 6 | Feb 18, 2022 |
DexCom
Sep 26, 2025
Maintains: Outperform
Price Target: $112 → $90
Current: $67.10
Upside: +34.13%
The Cooper Companies
Aug 28, 2025
Maintains: Outperform
Price Target: $97 → $85
Current: $67.55
Upside: +25.83%
Alcon
Aug 21, 2025
Maintains: Outperform
Price Target: $108 → $95
Current: $73.92
Upside: +28.52%
Beta Bionics
Jul 30, 2025
Maintains: Neutral
Price Target: $15 → $17
Current: $19.53
Upside: -12.95%
Henry Schein
Jul 14, 2025
Downgrades: Neutral
Price Target: $82 → $72
Current: $66.04
Upside: +9.02%
Envista Holdings
May 27, 2025
Upgrades: Outperform
Price Target: $21 → $23
Current: $20.35
Upside: +13.02%
Zimmer Biomet Holdings
May 6, 2025
Maintains: Outperform
Price Target: $130 → $115
Current: $98.24
Upside: +17.06%
Tandem Diabetes Care
May 1, 2025
Maintains: Neutral
Price Target: $33 → $24
Current: $12.00
Upside: +100.00%
Stryker
Oct 30, 2024
Maintains: Outperform
Price Target: $378 → $405
Current: $369.02
Upside: +9.75%
Align Technology
Oct 24, 2024
Maintains: Outperform
Price Target: $325 → $276
Current: $126.19
Upside: +118.72%
Dec 21, 2023
Upgrades: Outperform
Price Target: $180 → $238
Current: $318.00
Upside: -25.16%
Aug 4, 2023
Maintains: Outperform
Price Target: $67 → $70
Current: $29.99
Upside: +133.41%
Jul 28, 2023
Maintains: Outperform
Price Target: $53 → $61
Current: $14.90
Upside: +309.40%
Feb 18, 2022
Maintains: Outperform
Price Target: $78 → $67
Current: $12.50
Upside: +436.00%